Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | January 10, 2026 | January 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,430 |
Reported balance
After 2026-01-10 transaction · row 1
1 source rowRow 1 · 2026-01-10 · Exercise / conversion · Acquired 3,430 · Balance 3,430 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-10 · Exercise / conversion · Disposed 3,430 · Balance 0 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2026 Filed Jan 16, 2026 17:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionRestricted Stock Units · Derivative | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015489 · ownership.xml · derivative · entry 2 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| January 10, 2026 Filed Jan 16, 2026 17:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionCommon Stock | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015489 · ownership.xml · nonDerivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 17:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004924 · ownership.xml · derivative · entry 2 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: 100% of the total restricted stock units will vest on January 10, 2026. F3 · derivative.expiration_date: 100% of the total restricted stock units will vest on January 10, 2026. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 17:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 30,870 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004924 · ownership.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,870 Underlying: Common Stock · 30,870 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026. Read SEC document |
| May 01, 2023 Filed May 2, 2023 18:44 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 150,437 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026727 · doc4.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,437 Underlying: Common Stock · 150,437 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 18:08 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006355 · doc4.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 17:35 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006480 · doc4.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 20:10 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 1,167.21 | $0.00 Strike: $500.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025165 · doc4.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167.21 Underlying: Series X1 Convertible Preferred Stock · 1,167.21 shares Expires 2030-09-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 1,167.21 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c). F2 · derivative.underlying: Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 16:06 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0000899243-19-019601 · doc4.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-07-11 Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 17:52 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 9,100 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0000899243-18-016652 · doc4.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-06-13 Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:07 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0000899243-17-017764 · doc4.xml · derivative · entry 1 McBride John S. · CIK 0001618251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-06-30 F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.